Yahoo Finance

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

5-year overall survival (OS) rate for stereotactic body radiation therapy (SBRT) followed by cryoablation was 74%, compared to published studies reporting 5-year OS of 41% - 52% with SBRT alone SBRT ...
USA Today

Cryoablation: The Minimally Invasive Freezing Technology That’s a Game-Changer for Treating Low-Risk, Early-Stage Breast Cancer

Lumpectomy has been the standard of care for low-risk, early-stage breast cancer, but now cryoablation — freezing cancer tumors to kill them — is emerging as a new option. The FDA recently granted ...
Nasdaq

IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod

IceCure Medical Ltd ICCM recently announced that it has received marketing authorization from the FDA for its next-generation single probe cryoablation system, XSense Cryoablation System with ...
Benzinga.com

Freezing Cancer With IceCure: ProSense Cryoablation System Receives FDA Marketing Authorization For Early-Stage Breast Cancer Treatment

IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...
Nasdaq

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

CAESAREA, Israel, March 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...